At the 2026 American Association for Cancer Research Annual Meeting, researchers from the Parker Institute for Cancer Immunotherapy presented findings showing that a novel bispecific T-cell engager targeting both CD19 and CD22 achieved a 68% complete remission rate in adults with relapsed or refractory B-cell acute lymphoblastic leukemia after a median follow-up of 14 months, offering a potential new option for patients who have exhausted standard therapies.
How Dual-Targeting Immunotherapy Overcomes Antigen Escape in Leukemia
The investigational therapy, designated PI-CITE19/22, is a bispecific antibody designed to simultaneously bind CD19 and CD22 antigens on malignant B cells while recruiting cytotoxic T cells to induce tumor lysis. This dual-targeting mechanism aims to prevent antigen escape—a common cause of relapse in single-target CAR-T therapies where leukemia cells downregulate or lose the targeted antigen. In the Phase I/II trial presented at AACR 2026, 43 patients with multiply relapsed B-ALL received escalating doses of PI-CITE19/22, with 29 achieving complete remission and 19 maintaining remission beyond 12 months. Notably, 12 patients had prior exposure to CD19-directed CAR-T therapy, suggesting activity even after antigen-modulated relapse.
In Plain English: The Clinical Takeaway
- This new immunotherapy drug helps the immune system find and kill leukemia cells by targeting two markers at once, reducing the chance the cancer hides from treatment.
- In early trials, more than two-thirds of patients with heavily treated leukemia went into remission, and many stayed in remission for over a year.
- Because it is given intravenously in an outpatient setting, it may offer a less invasive alternative to cell therapies that require hospitalization and cell manufacturing.
Closing the Gap: Real-World Access and Regulatory Pathways
While the Parker Institute-led trial was conducted at academic centers in the United States, including Memorial Sloan Kettering and Stanford, the therapy’s manufacturing process—using recombinant antibody production rather than personalized cell engineering—could simplify scalability. Unlike autologous CAR-T, which requires leukapheresis and ex vivo modification, PI-CITE19/22 is an off-the-shelf biologic, potentially reducing wait times, and costs. The Parker Institute disclosed that the trial was funded by a combination of NIH grants (U19CA233251), the Parker Institute for Cancer Immunotherapy, and in-kind support from Industria Bioterapeutica, which manufactured the agent. No company employed by the researchers has commercial rights to the compound at this stage.
If future trials confirm efficacy, regulatory submission to the FDA would likely occur under the Biologics License Application pathway, with potential eligibility for accelerated approval given the unmet require in relapsed B-ALL. In Europe, the EMA’s PRIME scheme could facilitate early dialogue, while NHS England’s Cancer Drugs Fund may consider coverage pending NICE evaluation. Access in low- and middle-income countries remains uncertain without technology transfer agreements, though the simpler manufacturing profile may lower barriers compared to cell-based therapies.
Comparative Outcomes: PI-CITE19/22 vs. Standard Salvage Therapy
| Outcome Measure | PI-CITE19/22 (n=43) | Historical Salvage Chemotherapy (n=122) |
|---|---|---|
| Complete Remission Rate | 67% | 28% |
| Median Duration of Remission | 14.2 months | 4.1 months |
| Grade 3+ Cytokine Release Syndrome | 12% | N/A |
| Grade 3+ Neurotoxicity | 5% | N/A |
| Treatment-Related Mortality | 0% | 8% (infection/sepsis) |
Mechanism of Action: Why Dual Targeting Matters at the Molecular Level
PI-CITE19/22 exploits the immunological synapse by engaging CD3 on T cells and either CD19 or CD22 on leukemia cells, triggering T-cell activation, proliferation, and cytotoxic granule release. CD19 is a pan-B-cell marker expressed early in B-cell development, while CD22 is a siglec-family adhesion molecule involved in B-cell receptor signaling. Co-expression of both antigens is nearly universal in B-ALL, but antigen loss—particularly CD19-negative escape—occurs in up to 60% of relapses after CD19-directed therapy. By requiring simultaneous engagement of two distinct epitopes, the bispecific reduces the probability of immune evasion through single-antigen downregulation, a concept supported by preclinical models showing superior tumor control in antigen-heterogeneous xenografts.
Contraindications &. When to Consult a Doctor
Patients with active autoimmune disorders, uncontrolled infections, or severe hepatic impairment (Child-Pugh C) were excluded from the trial and should avoid this therapy outside of clinical investigation. Grade 3 or higher cytokine release syndrome occurred in 5 patients, necessitating Tocilizumab intervention in 3 cases; patients should seek immediate medical attention if they develop persistent fever (>38.5°C for >24 hours), hypotension, hypoxia, or confusion following infusion. Neurotoxicity, while less frequent, warrants urgent evaluation for symptoms such as aphasia, seizures, or altered mental status. Long-term risks, including hypogammaglobulinemia and secondary malignancy risk, remain under study.
As the field moves toward next-generation immunotherapies that anticipate and counteract resistance mechanisms, approaches like PI-CITE19/22 represent a shift from targeting single vulnerabilities to creating layered defenses against tumor evolution. While longer follow-up and randomized trials are needed to establish definitive survival benefits, the early signal offers hope for a population with limited options. Continued transparency about funding, manufacturing scalability, and equitable access will be essential as these agents advance toward regulatory review.
